Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

BESPOKE CRC: postoperative ctDNA positivity tracked with shorter disease-free survival in stage II and III disease

In the final MRD analysis of the observational BESPOKE CRC study presented at ASCO GI 2025, ctDNA positivity in the postoperative window was associated with inferior disease-free survival in stage II disease (HR 10.4) and stage III disease (HR 10.1) among patients with a result in that window.

Journal of Clinical Oncology